Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bioanalytical Systems Inc (NASDAQ:BASI)

1.65
Delayed Data
As of Aug 31
 +0.05 / +3.12%
Today’s Change
1.23
Today|||52-Week Range
2.60
-24.30%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$13.0M

Company Description

Bioanalytical Systems, Inc. operates as a pharmaceutical development company which, provides drug discovery, development services and analytical instruments. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The company operates through two business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. Bioanalytical Systems was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Contact Information

Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette Indiana 47906
P:(765) 463-4527
Investor Relations:
(765) 497-8409

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Jacqueline M. LemkePresident, Chief Executive Officer & Director
Jill BlumhoffDirector-Finance & Information Technology
Jeffrey PotrzebowskiCFO, VP-Finance & Head-Investor Relations
Philip A. DowningVice President-Preclinical Services
James Sevall BourdageVice President-Bioanalytical Operations